This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Rosuvastatin on Aortic Stenosis Progression (ASTRONOMER)

This study has been completed.
Ottawa Heart Institute Research Corporation
Information provided by:
AstraZeneca Identifier:
First received: November 25, 2008
Last updated: December 2, 2010
Last verified: December 2010
The purpose of this study is to assess the effects of rosuvastatin compared to usual care in patients diagnosed with aortic valvular stenosis. Patients must have a diagnosis of mild to moderate aortic stenosis (AS) and no clinical indication for the use of cholesterol lowering agents. A multi-centre, randomized, double-blind, placebo-controlled study, with a two year recruitment period, and a treatment duration of a minimum of 3 years from the time of the last patient randomized to a maximum of 5 years.

Condition Intervention Phase
Aortic Stenosis Drug: Rosuvastatin Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Cholesterol Lowering on the Progression of Aortic Stenosis in Patients With Mild to Moderate Aortic Stenosis (ASTRONOMER)Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and The Sub-Study Protocol.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The changes in transvalvular aortic velocities and the changes in aortic valve area. [ Time Frame: Between baseline and close-out measurments. ]

Secondary Outcome Measures:
  • The incidence and severity of adverse events, the clinically relevant changes in echocardiograms, and laboratory analysis will be compared between the two treatment groups. [ Time Frame: Baseline and minimum of 3 year follow-up. ]
  • The incidence and severity of adverse events, the clinically relevant changes in echocardiograms, and laboratory analysis will be compared between the two treatment groups. [ Time Frame: Between baseline and close-out measurments. ]

Estimated Enrollment: 378
Study Start Date: November 2002
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Rosuvastatin 40 mg
Drug: Rosuvastatin
40 mg, oral, single dose
Placebo Comparator: 2
Drug: Placebo
oral, single dose


Ages Eligible for Study:   18 Years to 82 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mild to moderate AS defined by peak Doppler aortic valve velocity 2.5 to 4 m/sec
  • Baseline LDL-C value must be within targeted level for all risk categories according to the Canadian Guidelines
  • Baseline triglyceride levels must be within target level for the risk categories

Exclusion Criteria:

  • Very mild AS defined by peak Doppler AS velocity <2.5m/sec, because the rate of progression is not well defined; Females of child bearing potential who do not practice adequate contraception.
  • Severe AS defined by peak Doppler AS velocity > 4m/sec. These patients are excluded because they will have a high probability of aortic valve replacement even without further AS progression.
  • Greater than moderate aortic regurgitation, defined as aortic jet width to aortic outflow tract ratio >0.45; Patients with diabetes or with a fasting blood sugar level > 7.0 mmol/L (must be confirmed with one repeat assay within 14 days).
  • Significant concomitant mitral valve disease, defined by > moderate mitral regurgitation (MR) or mitral valve area (MVA)< 1.5 cm2; A very high risk of CAD (10 year risk > 30%), according to the Canadian Guidelines.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00800800

Canada, Alberta
Research site
Calgary, Alberta, Canada
Research site
Edmonton, Alberta, Canada
Canada, British Columbia
Research site
Surrey, British Columbia, Canada
Research site
Vancouver, British Columbia, Canada
Research site
Victoria, British Columbia, Canada
Canada, Manitoba
Research site
Edmonton, Manitoba, Canada
Canada, Ontario
Research site
Brampton, Ontario, Canada
Research site
Cambridge, Ontario, Canada
Research site
Kitchener, Ontario, Canada
Research site
Montreal, Ontario, Canada
Research site
Ottawa, Ontario, Canada
Research site
Toronto, Ontario, Canada
Canada, Quebec
Research site
Montreal, Quebec, Canada
Research site
Halifax, Canada
Research site
St. John's, Canada
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Andrew Vieira, AstraZeneca Canada Identifier: NCT00800800     History of Changes
Other Study ID Numbers: DC-452-0003
Study First Received: November 25, 2008
Last Updated: December 2, 2010

Keywords provided by AstraZeneca:
progression of aortic stenosis

Additional relevant MeSH terms:
Aortic Valve Stenosis
Constriction, Pathologic
Disease Progression
Pathological Conditions, Anatomical
Disease Attributes
Pathologic Processes
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on September 21, 2017